Codexis to Report Second Quarter 2021 Financial Results on August 5
July 22 2021 - 4:05PM
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company
enabling the promise of synthetic biology, today announced that it
will report its financial results for the second quarter of 2021 on
Thursday, August 5, 2021, following the close of market. Codexis
management will host a conference call and webcast at 4:30 p.m.
Eastern Time to discuss the Company’s financial results and provide
a business update.
Participants may access the live webcast on the
Codexis Investor Relations website, where it will be archived for
90 days. The live call can be accessed by dialing 877-705-2976
(domestic) or 201-689-8798 (international), conference
ID #13721066. A replay of the call will be
available for 48 hours by dialing 877-660-6853 (domestic) or
201-612-7415 (international) conference ID #13721066.
About CodexisCodexis is a
leading enzyme engineering company leveraging its proprietary
CodeEvolver® platform to discover and develop novel, high
performance enzymes and novel biotherapeutics. Codexis enzymes have
applications in the sustainable manufacturing of pharmaceuticals,
food, and industrial products; the creation of the next generation
of life science tools; and as biologic therapeutics and in gene
therapy. The Company’s unique enzymes drive improvements such as
reduced energy usage, waste generation and capital utilization,
higher yields, higher fidelity diagnostics, and more efficacious
therapeutics. Codexis enzymes enable the promise of synthetic
biology to improve the health of people and the planet. For more
information, visit www.codexis.com.
Forward-Looking Statements To
the extent that statements contained in this press release are not
descriptions of historical facts regarding Codexis, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
You should not place undue reliance on these forward-looking
statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond
Codexis’ control and that could materially affect actual results.
Factors that could materially affect actual results include, among
others: Codexis’ dependence on its licensees and collaborators;
Codexis’ dependence on a limited number of products and customers
and potential adverse effects to Codexis’ business if its
customers’ products are not received well in the markets.
Additional information about factors that could materially affect
actual results can be found in Codexis’ Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on March
1, 2021, and in Codexis’ Quarterly Report on Form 10-Q filed with
the SEC on May 7, 2021, including under the caption “Risk Factors,”
and in Codexis’ other periodic reports filed with the SEC. Codexis
expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Relations Contact:Argot
PartnersStephanie Marks/Carrie McKim(212)
600-1902Codexis@argotpartners.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Apr 2023 to Apr 2024